SC
NKTR icon

Samlyn Capital’s Nektar Therapeutics NKTR Stock Holding History

Samlyn Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-644,470
Closed -$8.99M – 102
2024
Q4 		$8.99M Buy
644,470
+31,140
+5% +$549K 0.14% 91
2024
Q3 		$12M Sell
613,330
-17,196
-3% -$328K 0.18% 80
2024
Q2 		$11.7M Buy
+630,526
New +$13.3M 0.2% 84

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Samlyn Capital's NKTR Position: Q1 2025 in Review

Samlyn Capital sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 644,470 shares — an estimated $8.99M sold.

Samlyn Capital first reported a position in NKTR in Q2 2024 and held it in 3 quarters. The position peaked at $12M in Q3 2024. 155 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Samlyn Capital reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Samlyn Capital sold 644,470 Nektar Therapeutics shares in Q1 2025, an estimated $8.99M.
  • Samlyn Capital first reported a position in Nektar Therapeutics in Q2 2024 and held it in 3 quarters.
  • Samlyn Capital's Nektar Therapeutics position peaked at $12M in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Samlyn Capital's 13F filing for Q1 2025, filed 15 May 2025.